Using Infrared Spectroscopy for Real-Time Diagnostics During Brain Surgery
When using IR spectroscopy to examine freshly resected brain tissue in an operating room, what are you trying to achieve?
The end goal is to be able to detect the hard-to-see tumor borders during operations, because incomplete removal is linked to recurrence in many brain tumors. In soft tissues like the brain, these borders shift during the operation from preoperative magnetic resonance imaging (MRI) images. IR can give contrast in these low-contrast situations, and thus aid in reducing the number of surgeries a patient must endure. This initial study was focused more on determining where reliable spectral differences are between normal and tumor in fully hydrated tissue. Further studies will be needed to see how the identified signals “titrate” between normal and tumor tissue.
When analyzing brain tumors with IR spectroscopy, what biomarkers are you measuring? How precisely can these markers be differentiated in healthy and cancerous tissue, and to what extent do individual variances occur? Have the biomarkers been validated?
Chemicals produced by the tumor itself and then sensed by IR serve as the biomarkers. In the attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectra from tumor tissues, this results in fairly dramatic shifts in frequency and changes in absorbance. While full interpretation on a chemical level must await purification and structural characterization studies, it is apparent that there do seem to be reasonably large changes in the ATR-FTIR between the control brain tissues and the tumor ones.
In our recent study , we found a particular region that contains signals from extracellular molecules like collagen, whose triple helix structures give it a very distinctive IR signal. Collagens are overexpressed in many tumors, resulting in large changes in the IR. These changes were plotted in the recent paper we published in PLoS ONE (1). Dr. Deirdre Toher, a statistician at the University of the West of England in Bristol, helped me with some of the basic spectral preprocessing in large batches for the study.
A major lesson I gained from this trial — and when doing my literature survey for the recent publication — addresses your question about how to identify so-called “spectral biomarkers” or “fingerprints” for disease. Doing controls with healthy tissues and comparing and contrasting them with diseases can allow us to first determine where reliable differences occur. Comparison with tissues known to overexpress certain chemicals can help assign bands and determine roughly their percent contribution to the overall tissue spectrum.
Inter-individual variance for this measurement was something I was quite concerned about, which is why Dr. Ordtrud Uckermann, a neuroscientist at the Department of Neurosurgery in the Dresden University Hospital, and I designed a small control study to obtain the IR signals from normal, healthy mouse brains. The variation among the five individual animals was much lower than I expected it to be (particularly for waterlogged materials), and forthcoming manuscripts on this trial will illuminate this point.
What will be most interesting to see is how the IR spectra change between patients with the same diagnosis using traditional histochemistry. IR shall likely be much more sensitive to intrinsic, biochemical-level inter-individual differences in the phenotype of the tumor than any morphology-based method. This information will help biomedical scientists in the future design personalized treatments with physicians based on a patient’s unique biochemistry.
This is the preclinical trial, so validation is the next step. These initial results are reasonably promising, however, and illustrate that the core idea is sound.
You used a portable IR instrument with an ATR device with a particular beam path. What are the advantages of that beam path?
The major technical advantages of the ATR beam path lie in the ease of measurement it allows (no sample preparation is needed, just firm contact with the crystal) and the low penetration depth of the beam, which reduces the signal from water in freshly harvested tissues and living cell cultures.
Another nice feature of the ATR beam path is that it measures an averaged signal — slight alterations due to healthy fluctuations in cellular metabolism do not appear to affect tissue spectra. Dramatic changes in biochemistry such as those that occur during pathogenesis need to occur for the signal to alter. Thus, it is less prone to measure the “noise” that more sensitive instrumentation may pick up on in living systems.
Most IR studies of tissues are performed on dried specimens. When looking at fresh, hydrated tissues, how do you avoid having the strong IR signal of water overwhelm the signals from biochemicals in the tissues?
Figure 1: Left: A typical piece of resected human brain tumor tissue. Right: The ATR-FTIR spectrum of freshly resected brain tissue (solid) overlaid with the spectrum from a pH 7.5 isotonic buffer (dashed).
One of the major challenges remaining is explaining to the medical doctors how to interpret the data obtained from IR measurements. The team in the Department of Neurosurgery at the Dresden University Hospital is unique in the world as it has a spectroscopist, Dr. Gerald Steiner, and a neurosurgeon, Dr. Matthias Kirsch, both working on bringing this technology out of the lab and into the operating room. However, communicating this field as a whole to a broad medical audience will be challenging. Physicians and life scientists take very different courses in their training than physical scientists do, and this can make cross-disciplinary communication difficult.
What results have you obtained so far?
Thus far, we have determined a solid method for reducing the water signal, which seems to yield reliable measurements between identically prepared and fully hydrated biological samples. After comparing all the data sets — cells, animals, and human tumors — I located a particular region that appears to change reliably when going from normal to tumor tissue. Further trials will have to be orchestrated to confirm and enhance this initial data set.
How do the analyses using IR spectroscopy compare to those of traditional diagnostic methods in terms of accuracy?
Looking at the field as a whole, vibrational methods in particular offer major advantages over anything currently on the medical diagnostic market. This has been shown recently in a number of studies using IR mapping — particularly from Professor Max Diem’s group at Northeastern University and his company Cireca Theranostic, and a few other groups worldwide. IR mapping on air-dried tissues in particular has shown fantastic specificity and sensitivity compared to staining methods. The experiments I did in Dresden with the portable IR instrument are likely to be shown less accurate than the mapping experiments, because what I did is more of a “point biopsy” and the measurement is not spatially resolved. However, it is still more accurate and faster than most other options available to physicians, and given that it is sensitive to the tissue chemistry, it can in essence sense many different conditions in parallel.
Unlike many morphology-based methods for determining diagnosis, vibrational spectroscopy is objective and can greatly aid in reducing inter-observer variance in pathology. This will increase diagnostic accuracy and save both lives and money. It’s not that the pathologists are performing the “gold standard” tests (typically, histochemical and immunohistochemical staining) wrongly; the tests themselves do not ask the correct questions. We need to know “bulk” biochemical phenotype information from the tissue, and then we must combine this with genetic information to obtain complete maps of this molecular territory. Once we know the territory, we can work on issues like efficient drug delivery and finding new targets for therapies. Morphology and specific dyes and labels — although useful in their own ways — simply cannot give us all this information. Vibrational spectroscopy, although complex to analyze for tissues, can help make significant dents in classifying tissues by their chemical compositions.
How difficult is it for a surgeon to use spectroscopic analysis during surgery?
Currently, the surgeon would have to have a spectroscopist familiar with tissue IR interpretation in the operating room — and clearly this is not a viable option for the future. I did the analysis the old-fashioned way for this preliminary paper: I went through all the spectra that my undergraduate thesis student Jelena Tavkin (who is currently in a biophysics master’s program at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden) and I collected, and then found regions in the patient IR spectra that had clear, bulk alterations in frequency or absorbance from the control mouse spectra. Easy-to-use software will have to be designed explicitly for medical users. Physicians do not have time during operations to think about complex analysis.
Is one type of vibrational spectroscopy better suited to this work than another?
Raman spectroscopy has an obvious advantage over IR spectroscopy in that it is not sensitive to water vibrations due to symmetry. However, it takes a longer time to acquire a Raman spectrum than it does IR (unless you’re enhancing the Raman signal with methods like coherent anti-Stokes Raman spectroscopy, like the Xie group at Harvard does), and speed is important during surgery. Given the high quality spectra this portable instrument gives in under 1 min, I’d say it’s a very good option for conducting experiments inside of operating rooms on fresh, undegraded tissues. It’s small, fairly user-friendly, and yields data whose analysis is reasonably straightforward and easy to archive. However, the measurement with this device can only be done on tissue after it is harvested. Raman or ATR probes, or both, will be needed for true in vivo diagnostics.
When will this technique is ready for regular use by neurosurgeons?
This will depend a lot on funding. The field as a whole needs to lay a proper, statistically sound foundation for the medical applications of vibrational spectroscopy via a large clinical trial. It will also depend upon federal regulation for medical devices, which seems to be in a state of flux right now. Given funding, a full clinical trial using a portable ATR-FTIR device could go very rapidly — possibly in as little as 2 or 3 years, depending upon the patient load — as the data collection itself only takes a minute.
What are your next steps in this work?
Right now, we must build up a statistically significant number of results in these trials, both for normal controls, and diseased or cancerous tissue. The data we collect using this portable IR instrument can, in turn, be used to inform the more exacting Raman and IR mapping studies. One thing people must start considering immediately is how to create patient databanks in a secure manner that complies with medical regulations.
Ultimately, endoscopic probes that incorporate multiple different spectral modalities — Raman, IR, fluorescence, UV–vis — should be created for intraoperative diagnostics, as is being done by Professor Peter Notinger’s group at the University of Nottingham in the UK. They combine fluorescence and Raman data to diagnose skin cancer. Combining multiple spectral tests will greatly enhance diagnostic accuracy. Vibrational spectroscopy in particular will noninvasively provide valuable chemical information about the molecular phenotypes of disease, which will help pathologists and biomedical scientists understand the biochemical bedrocks that define life.
(1) A.L. Stelling et al., PLoS ONE 8(3), e58332 (2013). doi:10.1371/journal.pone.0058332.